Pilot Study of High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed High-Risk Neuroblastoma

Trial Profile

Pilot Study of High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed High-Risk Neuroblastoma

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Iobenguane (Primary) ; Cefixime; Irinotecan; Vincristine
  • Indications Neuroblastoma
  • Focus Adverse reactions
  • Acronyms MIBG-Irino
  • Most Recent Events

    • 19 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 18 Jan 2014 Planned End Date changed from 1 Nov 2013 to 1 May 2014 as reported by ClinicalTrials.gov registry record .
    • 17 May 2013 Planned end date changed from 1 Sep 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top